Back to Search
Start Over
Tumor mutational burden in non-small cell lung cancer—the pathologist’s point of view
- Publication Year :
- 2018
- Publisher :
- AME Publishing Company, 2018.
-
Abstract
- In non-small cell lung cancer (NSCLC), the pathologist has contributed to the development of personalized medicine from the determination of the right histological type to EGFR and ALK/ROS1 molecular screening for targeted therapies. With the development of immunotherapies, pathologists intervene forefront with programmed death-ligand 1 (PD-L1) immunohistochemical testing, companion test for pembrolizumab monotherapy, first line and complementary test to the other programmed cell death-1 (PD-1) PD-L1 inhibitors. Recently, tumor mutational burden has emerged as a promising tool to evaluate sensitivity to immunotherapy (IO). The pathologist has a crucial role in the setting of tumor mutational burden (TMB) testing for the selection and the preparation of the sample for high throughput molecular analysis, and in the first steps of the next-generation sequencing (NGS) workflow.
- Subjects :
- 0301 basic medicine
Pathology
medicine.medical_specialty
business.industry
medicine.medical_treatment
Cell
non-small cell lung cancer (NSCLC)
Immunotherapy
Pembrolizumab
Mini-Review
medicine.disease
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
medicine.anatomical_structure
Oncology
030220 oncology & carcinogenesis
medicine
ROS1
Personalized medicine
Non small cell
business
Lung cancer
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....d09e4b7a4e35516abd9fa37178330cba